Free Trial
NASDAQ:KOD

Kodiak Sciences Q2 2025 Earnings Report

Kodiak Sciences logo
$8.21 +0.12 (+1.48%)
Closing price 04:00 PM Eastern
Extended Trading
$8.24 +0.02 (+0.30%)
As of 06:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kodiak Sciences EPS Results

Actual EPS
N/A
Consensus EPS
-$1.01
Beat/Miss
N/A
One Year Ago EPS
N/A

Kodiak Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Kodiak Sciences Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 14, 2025
Conference Call Time
4:00PM ET

Conference Call Resources

Kodiak Sciences Earnings Headlines

Elon Leaves DOGE? Here’s What’s Next…
Early investors in Tesla saw 30,000% returns. SpaceX? Similar story. Now, Elon Musk is going all-in on something even bigger: artificial superintelligence. He’s calling it the next evolution of AI—and insiders are already calling it “AI 2.0.” The project is advancing quickly, and a key update could be announced as early as this summer. You can’t invest directly in Elon’s new tech—but there’s a backdoor way in.
Penny Stocks To Watch In July 2025
See More Kodiak Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kodiak Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kodiak Sciences and other key companies, straight to your email.

About Kodiak Sciences

Kodiak Sciences (NASDAQ:KOD), a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

View Kodiak Sciences Profile

More Earnings Resources from MarketBeat